Incyte Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte or view top-rated stocks.

Wall Street analysts have given Incyte a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Incyte saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 4,960,000 shares, a drop of 16.1% from the March 31st total of 5,910,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is presently 3.9 days.
View Incyte's Short Interest.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, May, 4th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.25. The biopharmaceutical company earned $604.72 million during the quarter, compared to the consensus estimate of $657.73 million. Incyte had a negative trailing twelve-month return on equity of 13.66% and a negative net margin of 13.62%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the business earned ($2.86) earnings per share.
View Incyte's earnings history.

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 14.6% and is now trading at $82.37.
View which stocks have been most impacted by COVID-19.

17 analysts have issued twelve-month price targets for Incyte's stock. Their forecasts range from $70.00 to $124.00. On average, they anticipate Incyte's stock price to reach $99.50 in the next year. This suggests a possible upside of 20.8% from the stock's current price.
View analysts' price targets for Incyte or view top-rated stocks among Wall Street analysts.

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of INCY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.04%), Geode Capital Management LLC (1.54%), Bellevue Group AG (1.37%), Northern Trust Corp (0.89%), The Manufacturers Life Insurance Company (0.69%) and Sumitomo Mitsui Trust Holdings Inc. (0.41%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Nissay Asset Management Corp Japan ADV, BlackRock Inc., Robeco Institutional Asset Management B.V., BNP Paribas Arbitrage SA, Assenagon Asset Management S.A., UBS Group AG, Northern Trust Corp, and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

INCY stock was purchased by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Geode Capital Management LLC, PGGM Investments, Country Trust Bank, Seizert Capital Partners LLC, Pura Vida Investments LLC, Sumitomo Mitsui Trust Holdings Inc., and The Manufacturers Life Insurance Company . Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $82.37.

Incyte has a market capitalization of $18.12 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis.

Incyte employs 1,773 workers across the globe.

Incyte was founded in 1991.

The official website for Incyte is www.incyte.com.

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]